SCHEMBL1542385

SCHEMBL1542385

CCc1cc(-c2ccc[nH]c2=O)cc(C(C)(C)C)c1OC

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 3/20 0.64
KDM4E B2RXH2 3/20 0.35
ALDH1A1 P00352 2/20 0.35
GAA P10253 2/20 0.35
ERBB2 P04626 2/20 0.35
EGFR P00533 1/20 0.35
CYP1A1 P04798 1/20 0.34
PDGFRB P09619 1/20 0.33
PTGS2 P35354 2/20 0.32
NPC1 O15118 1/20 0.32
RAB9A P51151 1/20 0.32
ATM Q13315 1/20 0.32
ERAP1 Q9NZ08 1/20 0.32
ABL1 P00519 1/20 0.31
ALPL P05186 1/20 0.31
TNFRSF1A P19438 1/20 0.31
MEN1 O00255 1/20 0.31
POLB P06746 1/20 0.31
MAPT P10636 1/20 0.31
THRB P10828 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12678828 0.89 CYP3A4 (0.61) CYP3A4KDM4EALDH1A1GAAERBB2
SCHEMBL1543433 0.87 CYP3A4 (0.61) CYP3A4ERBB2EGFRTNFRSF1AKMT2A
SCHEMBL1543205 0.86 CYP3A4 (0.74) CYP3A4ERBB2EGFRTNFRSF1AKMT2A
SCHEMBL1542374 0.85 CYP3A4 (0.62) CYP3A4EGFRPDGFRBTNFRSF1APOLB
SCHEMBL1543040 0.85 CYP3A4 (0.55) CYP3A4KDM4EALDH1A1GAAERBB2
SCHEMBL1542685 0.85 CYP3A4 (0.55) CYP3A4ERBB2EGFRCYP1A1PDGFRB
SCHEMBL1542866 0.84 CYP3A4 (0.73) CYP3A4KDM4EALDH1A1MEN1KMT2A
SCHEMBL2128598 0.84 CYP3A4 (0.54) CYP3A4ALDH1A1ERBB2EGFRCYP1A1
SCHEMBL2128925 0.84 CYP3A4 (0.54) CYP3A4KDM4EALDH1A1GAAERBB2
SCHEMBL2128919 0.81 CYP3A4 (0.52) CYP3A4ERBB2EGFRCYP1A1ABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8273773-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-09-25 US claimed
EP-2307372-B1 HETEROCYCLIC ANTIVIRAL COMPOUNDS HOFFMANN LA ROCHE (CH) 2012-04-25 EP claimed
EP-2307372-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. Hoffmann-La Roche AG (CH) 2011-04-13 EP claimed
WO-2010010017-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS F. HOFFMANN-LA ROCHE AG (CH) 2010-01-28 WO claimed
US-20100021423-A1 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC 2010-01-28 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100021423-A1 Heterocyclic antiviral compounds POLR2A, RRM2B, RRP1B CYP3A4 528/4885KDM4E 1962/4885ALDH1A1 1136/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.